Here are popular headlines for the week ending August 19, 2016.
“Drug Enforcement Administration chief Chuck Rosenberg says the decision is rooted in science. Rosenberg gave ‘enormous weight’ to conclusions by the Food and Drug Administration that marijuana has ‘no currently accepted medical use in treatment in the United States.'”
Schedule 1? Really? Marijuana is classified with heroin and LSD? It has no palliative benefits?
I guess we’re all just supposed to ignore the fact that the US gave itself Patent 6,630,507 for cannabinoids “useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.” Read the full patent abstract if you haven’t already.
Since the DEA apparently didn’t get the patent memo, medical marijuana advocates are pointing out the inconsistency by sharing photos of their hands with the patent number, 6630507, written on them.
The contradiction has left many people scratching their heads, including The Hill contributor Paul Armentano who writes, “There is nothing scientific about willful ignorance.”
We also heard this week of a new government policy to increase the supply of marijuana for medical studies. Advocates across the web received the news positively, but not so fast says Rachael Rettner of LiveScience.
Medical Cannabis advocates have more to celebrate, however. “The United States Court of Appeals for the Ninth Circuit has affirmed a lower court ruling that the Department of Justice cannot spend any funds prosecuting people complying with state-legal medical cannabis laws.”
And that brings me to my final link for this week’s roundup. Illinois residents could see chronic postoperative pain (C-POP) added to the list of approved medical conditions. I hope this list continues to grow until doctors are free to recommend cannabis as a treatment option to all patients who stand to benefit.
What are you currently reading about medical marijuana?